GlobalData on MSN8h
MSD reports topline outcomes from Phase III NSCLC trial of pembrolizumabMSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous ...
When Ed O. went to the ER for shortness of breath and trembling, he never imagined he’d receive a diagnosis of unresectable ...
AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
in patients with metastatic non-small cell lung cancer (NSCLC). The randomized, open-label phase 3 MK-3475A-D77 trial (ClinicalTrials.gov Identifier: NCT05722015) evaluated the pharmacokinetics (PK) ...
We’re excited to see that patients with advanced NSCLC have more access to treatment options because of noninvasive liquid ...
Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...
For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...
Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...
has recommended approval of Lazcluze in combination with Rybrevant for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). The CHMP ...
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...
During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback